The primary goal of the Developmental Research Program (DRP) of the Yale SPORE in Lung Cancer (YSILC) is to identify and fund innovative pilot projects that possess translational potential for making an impact in the field of lung cancer in the areas of risk assessment; early detection; biomarkers for prognosis, therapy, and prediction; biology; and novel treatment approaches. Investigators and projects of funded developmental research projects are strongly encouraged to collaborate with other investigators within and outside of Yale, including other SPORE research communities, with the goal that these projects will evolve into independent full SPORE projects or equivalent scale studies. The objective of the YSILC DRP is to develop innovative lung cancer translational research programs. To achieve this goal, we propose the following three specific aims:
Specific Aim 1. To identify and recruit innovative pilot projects with translational potential for lung cancer.
Specific Aim 2. To support new research opportunities for lung cancer by funding innovative pilot projects.
Specific Aim 3. To enhance collaborations between SPORE full research projects and DRP investigators (current and potential) and to promote DRP projects to potential full SPORE or equivalent scale projects. Pilot projects funded by the DRP mechanism are strongly encouraged to collaborate with intra- and inter- SPORE projects. Projects making significant progress will be considered to be incorporated into a full project if there are any programmatic needs and upon agreement of the YSILC leadership in consultation with the Internal Advisory Board, External Advisory Board and NCI staff.
PROGRAM NARRATIVE The objective of this Developmental Research Program is to foster and develop innovative lung cancer translational research programs with objectives that align with the overall goals of the Yale SPORE in Lung Cancer. Projects of the highest caliber will be sought to possibly serve as replacements for the primary SPORE projects should productivity lag or other unforeseen circumstances arise.
|Wilson, Frederick H; Politi, Katerina (2018) ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discov 8:676-678|
|Wang, Guangchuan; Chow, Ryan D; Ye, Lupeng et al. (2018) Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci Adv 4:eaao5508|
|Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573|
|Anastasiadou, Eleni; Jacob, Leni S; Slack, Frank J (2018) Non-coding RNA networks in cancer. Nat Rev Cancer 18:5-18|
|Bisserier, Malik; Wajapeyee, Narendra (2018) Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Blood 131:2125-2137|
|Chow, Ryan D; Chen, Sidi (2018) Cancer CRISPR Screens In Vivo. Trends Cancer 4:349-358|
|Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270|
|Goldberg, Sarah B; Narayan, Azeet; Kole, Adam J et al. (2018) Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin Cancer Res 24:1872-1880|
|Gilles, Maud-Emmanuelle; Slack, Frank J (2018) Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opin Ther Targets 22:929-939|
|Nagarajan, Maxwell B; Tentori, Augusto M; Zhang, Wen Cai et al. (2018) Nonfouling, Encoded Hydrogel Microparticles for Multiplex MicroRNA Profiling Directly from Formalin-Fixed, Paraffin-Embedded Tissue. Anal Chem 90:10279-10285|
Showing the most recent 10 out of 74 publications